Yahoo Web Search

  1. Yahoo Finance Results

  2. This has lagged the Medical sector's loss of 9.67% and the S&P 500's loss of 8.82% in that time. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $20.11 billion ...

  3. Johnson & Johnson (JNJ) closed the most recent trading day at $128.93, moving -0.79% from the previous trading session. This has lagged the Medical sector's loss of 3.81% and the ...

  4. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ.

  5. Stocks recently featured in the blog include: Visa V, Coca-Cola KO, AbbVie ABBV, Johnson & Johnson JNJ and Duke Energy DUK.

  6. Why Johnson & Johnson Stock is Clearly Set to Rise Again

    InvestorPlace via Yahoo FinanceJan 03 18:24 PM

    Top Stock Picks From the Street's Best Analysts Management credits the relaunch of its iconic Johnson's Baby brand in the U.S. for the strong quarter. The pharmaceutical sector outperformed ...

  7. While the award was eye-popping -- the sixth-largest ever in a product-defect case -- J&J may pay far less, or nothing. Indeed, of the 25 largest U.S. jury awards, 23 were reversed, drastically ...

  8. The message doubles down on the stance the company has taken to defend against lawsuits in which about 11,700 plaintiffs allege that the J&J talc they used in past decades caused their cancer ...

  9. Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner ...

  10. Why Johnson & Johnson Stock Fell 12% in December

    Motley Fool via Yahoo FinanceJan 09 16:36 PM

    Johnson & Johnson (NYSE: JNJ) shares trailed the market last month as the stock lost 12% compared to a 9% slump in the S&P 500, according to data provided by S&P Global Market ...

  11. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.